The Medicines Company (MDCO) PT Trimmed to $50 at Leerink After Removing MDCO-216

November 8, 2016 6:35 AM EST
Get Alerts MDCO Hot Sheet
Price: $36.02 --0%

Rating Summary:
    15 Buy, 4 Hold, 0 Sell

Rating Trend: Up Up

Today's Overall Ratings:
    Up: 28 | Down: 28 | New: 23
Trade MDCO Now!
Join SI Premium – FREE

Get the Pulse of the Market with's Pulse Picks. Get your Free Trial here.

Leerink Partners analyst Joseph Schwartz reiterated an Outperform rating but trimmed his price target on The Medicines Company (NASDAQ: MDCO) to $50.00 (from $53.00) after removing MDCO-216 from their model after the company announced the immediate discontinuation of its MDCO-216 (APoA-1 Milano) clinical development program for this investigational cholesterol efflux promoter.

Schwartz commented, "The MILANO-PILOT trial reportedly did not show efficacy on intracoronary atherosclerotic plaque, although the drug did maintain its strong safety profile. Many investors had low confidence in this program's probability of success and worried about future development costs, so there is some silver lining to this negative news in regard to near-term development cost savings that can be reallocated to other pipeline programs. Reiterate Outperform, and we are reducing our price target to $50 (from $53) by removing MDCO-216 from our model."

For an analyst ratings summary and ratings history on The Medicines Company click here. For more ratings news on The Medicines Company click here.

Shares of The Medicines Company closed at $32.52 yesterday.

Serious News for Serious Traders! Try Premium Free!

You May Also Be Interested In

Related Categories

Analyst Comments, Analyst PT Change, FDA

Add Your Comment